Perflubutane

Summary

Perflubutane (CHEMBL2104979) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including portal hypertension and pancreatic ductal adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 19
• Chemistry: 238.03 Da · C4F10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104979
Name	Perflubutane
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9638
ChEBI	CHEBI:134964
Molecular formula	C4F10
Molecular weight	238.03
InChIKey	KAVGMUDTWQVPDF-UHFFFAOYSA-N

SMILES: C(C(C(F)(F)F)(F)F)(C(F)(F)F)(F)F

IUPAC name: 1,1,1,2,2,3,3,4,4,4-decafluorobutane

ChEBI definition: A fluorocarbon that is butane in which all of the hydrogens have been replaced by fluorines. Microbubbles of preflubutane are used in the ultrasound contrast agent BR14.

Also known as: AI-700, Perflubutane, Perflubutano, Sonazoid, PERFLUBUTANE

Patent coverage: 2,935 distinct patent families (8,502 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
portal hypertension	2	MONDO:0005080	EFO:0000666
pancreatic ductal adenocarcinoma	1	MONDO:0005184	MONDO:0005184

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
Not specified	5
PHASE3	3
PHASE2	3
EARLY_PHASE1	3
PHASE1/PHASE2	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07310758	PHASE2/PHASE3	RECRUITING	Contrast-enhanced Ultrasound for Sentinel Node Detection
NCT00669851	PHASE3	COMPLETED	Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study
NCT02651090	PHASE3	WITHDRAWN	Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI
NCT04006275	PHASE3	UNKNOWN	Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
NCT04821284	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
NCT07145801	PHASE2	RECRUITING	Y-90 Treatment Response Using Transarterial Radioembolization
NCT02652923	PHASE1/PHASE2	COMPLETED	Contrast Ultrasound Detection of Sentinel Lymph Nodes
NCT02733029	PHASE2	COMPLETED	Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
NCT03245255	PHASE2	COMPLETED	Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
NCT00156780	PHASE1	COMPLETED	Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
NCT02968680	PHASE1	TERMINATED	Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
NCT03009266	EARLY_PHASE1	UNKNOWN	Ischemic Memory Imaging With Myocardial Contrast Echocardiography
NCT03578224	EARLY_PHASE1	COMPLETED	Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer
NCT05105087	EARLY_PHASE1	COMPLETED	Gynecological Sentinel Lymph Nodes CEUS
NCT07590284	Not specified	NOT_YET_RECRUITING	Sonazoid CEUS for Early HCC Surveillance
NCT02737865	Not specified	COMPLETED	Superb Microvascular Imaging in Focal Nodular Hyperplasia
NCT04487288	Not specified	UNKNOWN	Added Value in Combined Use of Fusion Imaging and Contrast-enhanced Ultrasonography
NCT04686942	Not specified	UNKNOWN	Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm
NCT04961775	Not specified	UNKNOWN	A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).